SCHEMBL2529491

SCHEMBL2529491

CCS(=O)(=O)N1CCN(c2cnc(N)c(-c3nnc(-c4ccco4)o3)n2)CC1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ATR Q13535 12/20 0.50
ALDH1A1 P00352 4/20 0.41
MAPT P10636 3/20 0.41
KDM4E B2RXH2 3/20 0.41
CKS1B P61024 1/20 0.39
SKP1 P63208 1/20 0.39
SKP2 Q13309 1/20 0.39
NPC1 O15118 1/20 0.39
TP53 P04637 1/20 0.39
GAA P10253 1/20 0.39
HPGD P15428 1/20 0.39
TSHR P16473 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HSD17B10 Q99714 1/20 0.39
GSK3B P49841 1/20 0.38
PRKDC P78527 1/20 0.38
PTPN11 Q06124 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL615700 0.85 ATR (0.61) ATRGSK3BPRKDC
SCHEMBL2492765 0.83 ATR (0.45) ATRALDH1A1MAPTKDM4EHSD17B10
SCHEMBL2491689 0.82 ATR (0.46) ATRALDH1A1MAPTKDM4ENPC1
SCHEMBL2497637 0.82 ATR (0.46) ATRALDH1A1MAPTKDM4ENPC1
SCHEMBL2493587 0.82 ATR (0.46) ATRALDH1A1MAPTKDM4ENPC1
SCHEMBL2527297 0.81 ATR (0.52) ATRGSK3BPRKDC
SCHEMBL10255406 0.81 MAPT (0.42) ALDH1A1MAPTKDM4ENPC1TP53
SCHEMBL2527580 0.80 ATR (0.53) ATRGSK3BPRKDC
SCHEMBL2489781 0.79 ATR (0.43) ATRALDH1A1MAPTKDM4EGSK3B
SCHEMBL10255200 0.79 ATR (0.51) ATRALDH1A1MAPTKDM4EGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8410112-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-04-02 US disclosed
US-20120040020-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-16 US disclosed
EP-2370424-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE Vertex Pharmaceuticals Incorporated (US) 2011-10-05 EP disclosed
WO-2010054398-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040020-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK2, CHEK1 ATR 1/4885ALDH1A1 3958/4885MAPT 3458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.